NCT07213115 is a clinical trial of Gastrectomy+ chemotherapy in Gastric (Stomach) Cancer, sponsored by Medizinische Hochschule Brandenburg Theodor Fontane.

Who is sponsoring NCT07213115?

NCT07213115 is sponsored by Medizinische Hochschule Brandenburg Theodor Fontane.

What drugs are being tested in NCT07213115?

Interventions in NCT07213115: Gastrectomy+ chemotherapy.

What condition does NCT07213115 study?

NCT07213115 studies Gastric (Stomach) Cancer, Sex Difference.

Is NCT07213115 still recruiting?

NCT07213115 is currently completed. Last updated 8 October 2025.

Last reviewed 2025-10-08 · How we verify

NCT07213115

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Epidemiology and Treatment of Gastric Cancer

Completed Last updated 8 October 2025

What this trial tests

trial testing Gastrectomy+ chemotherapy in Gastric (Stomach) Cancer in 8,582 participants. Completed in 31 December 2020.

Timeline

1 January 2000

Primary endpoint
31 December 2020

31 December 2020

Quick facts

Lead sponsor	Medizinische Hochschule Brandenburg Theodor Fontane
Status	Completed
Study type	OBSERVATIONAL
Enrollment	8,582
Start date	1 January 2000
Primary completion	31 December 2020
Estimated completion	31 December 2020

Drugs / interventions tested

Gastrectomy+ chemotherapy — full drug profile →

Conditions studied

Gastric (Stomach) Cancer — all drugs for Gastric (Stomach) Cancer →
Sex Difference — all drugs for Sex Difference →

Sponsor

Medizinische Hochschule Brandenburg Theodor Fontane

Who can join

18 and older, any sex, with Gastric (Stomach) Cancer or Sex Difference. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

According to recent statistics, the incidence and mortality from gastric cancer are both worldwide in fifth place in terms of ranking. Gastric cancer is more common in males than in females. This difference in the incidence between males and females is likely due to the difference in exposure to some risk factors like Helicobacter pylori infection, family history of gastric cancer, dietary habits, smoking and alcohol. However these factors do not completely explain the different characteristics of gastric cancer between the sexes. Some studies have concluded that exposure to estrogen could reduce the risk of gastric cancer. There is a lack of current population based and real world data on sex and age differences in gastric cancer care. Analyses of sex differences are primarily originate from Asia or focusing on older cohorts. In the Netherlands, Kalff et al. conducted a study with patients with gastric adenocarcinoma (n=2 072) registered in the Dutch Upper GI Cancer Audit between 2011 and 2016. In this study, patients without metastatic gastric cancer and with an elective surgery were included. To close this sex and age data gap for patients including those with UICC IV stage and without surgery, the aim of our study was to analyze the sex and age differences in clinicopathological features and staging in gastric adenocarcinoma with cancer registry data from the Federal State of Brandenburg from 2000 to 2020.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Sex and Age Differences in Clinicopathological Characteristics of Gastric Cancer.
Schildberg C, Weber U, Dietrich N, Seeland U, et al · · 2025 · PMID 41302930 · DOI 10.3390/jcm14227894

Verify or expand the search:

Other recruiting trials for Gastric (Stomach) Cancer

Currently open trials in the same condition.

NCT07447050 — Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial · Phase 2 · recruiting
NCT07371663 — An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07481110 — Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Gastric Cancers in Algeria · recruiting
NCT06943807 — Prospective Gastric Cancer Screening With Fecal Multi-target DNA Analysis · recruiting
NCT06896370 — An Observational Study for Gastric Cancer in Carriers of High Risk Helicobacter Pylori · recruiting

Other Medizinische Hochschule Brandenburg Theodor Fontane trials

Trials by the same sponsor.

NCT06902337 — Gender Differences in Gastric Cancer Care and Its Adherence to Guidelines in Germany · active not recruiting
NCT07017153 — Patient Decision Aids for Hypertension: A Pilot Study · NA · completed
NCT06575582 — Digital Navigators for Acceptance and Competence Development with Mental Health Apps · NA · recruiting
NCT06631560 — Hepatitis E Virus Infection in Oncological Patients · NA · completed
NCT03052283 — Development and Validation of a Disease Specific PROM to Assess Abdominal Involvement in Patients With CF (CFAbd-Score) · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07213115 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medizinische Hochschule Brandenburg Theodor Fontane
Last refreshed: 8 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07213115.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing